{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:07:33Z","timestamp":1789452453935,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clgc.2025.102335","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T20:34:41Z","timestamp":1742243681000},"page":"102335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1423-5295","authenticated-orcid":false,"given":"Daniel M.","family":"Geynisman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Chepynoga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9996-1961","authenticated-orcid":false,"given":"Georgia","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Tate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Kurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miraj Y.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siguroli","family":"Teitsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronac","family":"Mamtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102335_bib0001","first-page":"99","article-title":"Radical cystectomy for urothelial cancer of the bladder: contemporary advances","volume":"59","author":"Manoharan","year":"2007","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.clgc.2025.102335_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2021.05.009","article-title":"Outcomes for muscle-invasive bladder cancer with radical cystectomy or trimodal therapy in US veterans","volume":"30","author":"Kumar","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2025.102335_bib0003","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11255-022-03339-6","article-title":"Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case\u2013control matching study","volume":"54","author":"van Ginkel","year":"2022","journal-title":"Int Urol Nephrol"},{"issue":"suppl 7","key":"10.1016\/j.clgc.2025.102335_bib0004","doi-asserted-by":"crossref","first-page":"S1342","DOI":"10.1016\/j.annonc.2022.07.1836","article-title":"1758P Characteristics, management and survival outcomes of French patients (pts) with muscle invasive bladder cancer (MIBC) at high risk of recurrence (MIBC-HR): a study based on the COBLAnCE cohort","volume":"33","author":"Fraslin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102335_bib0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00345-017-2115-4","article-title":"Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature","volume":"36","author":"Mari","year":"2018","journal-title":"World J Urol"},{"issue":"6 suppl 7","key":"10.1016\/j.clgc.2025.102335_bib0006","first-page":"S237","article-title":"Surveillance strategies after definitive therapy of invasive bladder cancer","volume":"3","author":"Cagiannos","year":"2009","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2025.102335_bib0007","unstructured":"US Food and Drug Administration. FDA Approves nivolumab for Adjuvant Treatment of Urothelial Carcinoma. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-adjuvant-treatment-urothelial-carcinoma. Accessed May 12, 2023."},{"key":"10.1016\/j.clgc.2025.102335_bib0008","unstructured":"European Commission, Public Health. Union Register of medicinal products. Available at: https:\/\/health.ec.europa.eu\/medicinal-products\/union-register_en. Accessed June 15, 2024."},{"key":"10.1016\/j.clgc.2025.102335_bib0009","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102335_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102335_bib0011","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jval.2023.03.039","article-title":"P27 The impact of incorporating survival heterogeneity into modeling of survival outcomes for patients with muscle-invasive bladder cancer after radical resection: analyses from a retrospective real-world study in France","volume":"26","author":"Chepynoga","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.clgc.2025.102335_bib0012","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s41669-021-00260-z","article-title":"Mixture cure models in oncology: a tutorial and practical guidance","volume":"5","author":"Felizzi","year":"2021","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.clgc.2025.102335_bib0013","series-title":"Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe","article-title":"Modeling and comparison of non-disease-related survival (NDRS) using local lifetables and reported trial data: a case study from adjuvant treatment of muscle-invasive urothelial carcinoma","author":"Srinivasan","year":"2022"},{"key":"10.1016\/j.clgc.2025.102335_bib0014","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/biostatistics\/kxl030","article-title":"Estimating and modeling the cure fraction in population-based cancer survival analysis","volume":"8","author":"Lambert","year":"2007","journal-title":"Biostatistics"},{"key":"10.1016\/j.clgc.2025.102335_bib0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/(SICI)1097-0258(19990228)18:4<441::AID-SIM23>3.0.CO;2-M","article-title":"Mixture models for cancer survival analysis: application to population-based data with covariates","volume":"18","author":"De Angelis","year":"1999","journal-title":"Stat Med"},{"issue":"suppl 5","key":"10.1016\/j.clgc.2025.102335_bib0016","doi-asserted-by":"crossref","first-page":"v533","DOI":"10.1093\/annonc\/mdz255","article-title":"Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III\/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial","volume":"30","author":"Weber","year":"2019","journal-title":"Ann Oncol"},{"issue":"suppl 7","key":"10.1016\/j.clgc.2025.102335_bib0017","doi-asserted-by":"crossref","first-page":"S1105","DOI":"10.1016\/j.annonc.2022.07.1336","article-title":"1218P Long-term survivorship rates among chemotherapy refractory or intolerant advanced esophageal squamous cell carcinoma (aESCC) patients treated with nivolumab (NIVO)","volume":"33","author":"Ajani","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102335_bib0018","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13696998.2020.1857960","article-title":"A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer","volume":"24","author":"Roth","year":"2021","journal-title":"J Med Econ"},{"issue":"suppl 7","key":"10.1016\/j.clgc.2025.102335_bib0019","doi-asserted-by":"crossref","first-page":"S1210","DOI":"10.1016\/j.annonc.2022.07.1559","article-title":"1456P Long-term survivorship rates for first-line intermediate or poor (I\/P) risk advanced renal cell carcinoma (aRCC) patients achieving objective response (OR) with nivolumab plus ipilimumab (N+ I)","volume":"33","author":"George","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102335_bib0020","series-title":"American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium","article-title":"Long-term survivorship rates among previously treated advanced renal cell carcinoma patients receiving nivolumab: analyses based on \u2265 7 years of follow-up from CheckMate 025 trial","author":"George","year":"2023"},{"key":"10.1016\/j.clgc.2025.102335_bib0021","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s12325-023-02444-x","article-title":"Cost-effectiveness of lisocabtagene maraleucel versus axicabtagene ciloleucel and tisagenlecleucel in the third-line or later treatment setting for relapsed or refractory large B-cell lymphoma in the United States","volume":"40","author":"Parker","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.clgc.2025.102335_bib0022","article-title":"Heterogeneity in survival with immune checkpoint inhibitors and its implications for survival extrapolations: a case study in advanced melanoma","volume":"7","author":"Federico Paly","year":"2022","journal-title":"MDM Policy Pract"},{"key":"10.1016\/j.clgc.2025.102335_bib0023","unstructured":"Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. Report by the Decision Support Unit, June 2011. School of Health and Related Research, University of Sheffield, UK. Available at: https:\/\/www.sheffield.ac.uk\/sites\/default\/files\/2022-02\/TSD14-Survival-analysis.updated-March-2013.v2.pdf. Accessed January 15, 2025."},{"key":"10.1016\/j.clgc.2025.102335_bib0024","unstructured":"World Health Organization. Life tables. Available at: https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/indicator-groups\/indicator-group-details\/GHO\/gho-ghe-global-health-estimates-life-tables. Accessed: Last update 2019."},{"key":"10.1016\/j.clgc.2025.102335_bib0025","unstructured":"Rutherford M., Lambert P.C., Sweeting M.J., et al. NICE DSU technical support document 21: Flexible methods for survival analysis. Report by the Decision Support Unit, January 2020. School of Health and Related Research, University of Sheffield, UK. Available at: https:\/\/www.sheffield.ac.uk\/media\/34188\/download?attachment. Accessed January 15, 2025."},{"key":"10.1016\/j.clgc.2025.102335_bib0026","first-page":"28","article-title":"Package \u2018survival\u2019","volume":"128","author":"Therneau","year":"2015","journal-title":"R Top Doc"},{"key":"10.1016\/j.clgc.2025.102335_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v070.i08","article-title":"flexsurv: a platform for parametric survival modeling in R","volume":"70","author":"Jackson","year":"2016","journal-title":"J Stat Softw"},{"key":"10.1016\/j.clgc.2025.102335_bib0028","unstructured":"Gentleman R., Winsemius M.D. Package \u2018muhaz\u2019. 2015."},{"issue":"suppl 7","key":"10.1016\/j.clgc.2025.102335_bib0029","doi-asserted-by":"crossref","first-page":"S1335","DOI":"10.1016\/j.annonc.2022.07.1824","article-title":"1746P Disease-free survival (DFS) and distant metastasis-free survival (DMFS) as surrogates for overall survival (OS) in adjuvant treatment of muscle-invasive bladder cancer (MIBC)","volume":"33","author":"Sternberg","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102335_bib0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102335_bib0031","unstructured":"Witjes J.A., Bruins H.M., Carri\u00f3n A., et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer. Available at: https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer. Accessed: January 16, 2025."},{"key":"10.1016\/j.clgc.2025.102335_bib0032","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102335_bib0033","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102335_bib0034","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jncimonographs\/lgu015","article-title":"Current estimates of the cure fraction: a feasibility study of statistical cure for breast and colorectal cancer","volume":"2014","author":"Stedman","year":"2014","journal-title":"J Natl Cancer Inst Monogr"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T07:26:01Z","timestamp":1754551561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1558767325000369"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102335","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102335"}}